middle.news
How INOVIQ’s Exclusive Licence Could Revolutionize Early Ovarian Cancer Detection
9:46am on Friday 26th of September, 2025 AEST
•
Healthcare
Read Story
How INOVIQ’s Exclusive Licence Could Revolutionize Early Ovarian Cancer Detection
9:46am on Friday 26th of September, 2025 AEST
Key Points
Exclusive worldwide licence secured from UniQuest for ovarian cancer biomarker IP
EXO-OC™ test shows 100% sensitivity for early-stage ovarian cancer detection
Plans to launch as a Laboratory Developed Test (LDT) in the US by December 2026
Licence includes upfront payment, milestone fees, and tiered royalties
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inoviq (ASX:IIQ)
OPEN ARTICLE